Details for New Drug Application (NDA): 200834
✉ Email this page to a colleague
The generic ingredient in VENLAFAXINE HYDROCHLORIDE is venlafaxine hydrochloride. There are seventy-one drug master file entries for this compound. Sixty-two suppliers are listed for this compound. Additional details are available on the venlafaxine hydrochloride profile page.
Summary for 200834
| Tradename: | VENLAFAXINE HYDROCHLORIDE |
| Applicant: | Aurobindo Pharma Ltd |
| Ingredient: | venlafaxine hydrochloride |
| Patents: | 0 |
Pharmacology for NDA: 200834
| Mechanism of Action | Norepinephrine Uptake Inhibitors Serotonin Uptake Inhibitors |
Medical Subject Heading (MeSH) Categories for 200834
Suppliers and Packaging for NDA: 200834
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| VENLAFAXINE HYDROCHLORIDE | venlafaxine hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 200834 | ANDA | Major Pharmaceuticals | 0904-7487 | 0904-7487-61 | 100 BLISTER PACK in 1 CARTON (0904-7487-61) / 1 CAPSULE, EXTENDED RELEASE in 1 BLISTER PACK |
| VENLAFAXINE HYDROCHLORIDE | venlafaxine hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 200834 | ANDA | Major Pharmaceuticals | 0904-7488 | 0904-7488-61 | 100 BLISTER PACK in 1 CARTON (0904-7488-61) / 1 CAPSULE, EXTENDED RELEASE in 1 BLISTER PACK |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | CAPSULE, EXTENDED RELEASE;ORAL | Strength | EQ 37.5MG BASE | ||||
| Approval Date: | Apr 14, 2011 | TE: | AB | RLD: | No | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | CAPSULE, EXTENDED RELEASE;ORAL | Strength | EQ 75MG BASE | ||||
| Approval Date: | Apr 14, 2011 | TE: | AB | RLD: | No | ||||
Profile for product number 003
| Active Rx/OTC/Discontinued: | RX | Dosage: | CAPSULE, EXTENDED RELEASE;ORAL | Strength | EQ 150MG BASE | ||||
| Approval Date: | Apr 14, 2011 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
